Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion type Assertion NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_head.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion evidence source_evidence_literature NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion SIO_000772 11455976 NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion wasDerivedFrom befree-20150227 NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion wasGeneratedBy ECO_0000203 NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.